Trial Profile
An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis [EXTENSION OF 700008236].
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 21 Mar 2014
Price :
$35
*
At a glance
- Drugs Dirucotide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms MAESTRO-02
- Sponsors Eli Lilly and Company
- 21 Mar 2014 New trial record